1. The new standard for evaluating the efficacy of solid tumors: RECIST (Response Evaluation Criteria in Solid Tumors) Complete remission (CR, complete response) Partial remission (PR, partial response) Zhang Ruixiang, Department of Thoracic Surgery, Henan Tumor Hospital Disease stability (SD, stable disease) Disease progression (PD, progressive disease) stable disease (SD, stable disease) Progressive disease (PD, progressive disease) Note: If the longest diameter of only one target lesion increases by ≥20%, and the sum of the longest diameters of all recorded target lesions does not increase by 20%, it should not be evaluated as “PD”. 2. OS (overall survival) The time from randomization to death from any cause. Duration of overall response (CR or PR) The time from the first CR or PR to the first diagnosis of PD or relapse. Duration of stable disease (DSD) The period of time from the start of treatment to the time when the disease is evaluated as progressive. Disease-free survival (DFS) or disease-free survival time is the time from randomization to the first relapse or death. Progression-free survival (PFS, progression-free survival) The time between enrollment and tumor progression or death. Time to disease progression (TTP, Time to Progression) The time from the start of randomization to the occurrence of disease progression or death. Time to Treatment Failure (TTF, time to failure) The time from the start of randomization to treatment discontinuation/termination, including any reasons for discontinuation/termination. Disease control rate (DCR, disease control rate): CR+PR+SD. Objective Response Rate (ORR, Objective Response Rate) The proportion of patients whose tumors have shrunk by a certain amount and have remained there for a certain period of time, including cases of CR+PR. ORR (overall response rate) The proportion of treated CR+PR patients to the total number of evaluable cases. Response rate (RR, response rate) Percentage of patients achieving CR and PR over the total number of patients in the same period. CBR (clinical benefit rate): CR+PR+SD.